Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q3 2024 Earnings Presentation
17 slides from Q-linea Ab's earnings presentation, Nov 5, 2024
Slide 1: Presentation Q3(24)
Sustainable healthcare for a new generation Presentation Q3(24) November 5, 2024
Slide 2: Disclaimer
Disclaimer THIS PERESNTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. T
Slide 3: Key messages for today
Key messages for today Global market potential for ASTar of 5 – 7m annual tests weighted 1 towards largest hospitals and labs Momentum growing in US with expanding commercial 2 pipeline and first contract discussions already ongoing 3 New lower cost position established following restructuring progr
Slide 4: Q3 highlights: First commercial evaluations completed in US
Q3 highlights| First commercial evaluations completed in US Four overall areas of focus and progress during the quarter • Multiple commercial evaluations ongoing in US; several have completed and are in contract negotiation phase Commercial • Ambition to have completed or initiated a dozen-plus US e
Slide 5: ASTar: Revolutionizing AST
ASTar: Revolutionizing AST ~6 ~2 1st Hours Minutes Fully-automated, turn-around time Hands-on time random access platform ➢ Save lives ➢ Simple interface ➢ Comprehensive menu ➢ Save money ➢ Load-and-Go ➢ High reproducibility ➢ Reduces clinical effort ➢ Minimal training need ➢ High throughput with 12
Slide 6: Global AST market: ASTar targeting market of ~6m annual blood infection patients
Global AST market | ASTar targeting market of ~6m annual blood infection patients Potential to expand addressable market by 2 – 3x with additional indications Microbiology ~30m inpatient tests annually1 ❖ ASTar initially focused on Blood infections 80% 15% 5% • ~25% of total microbiology lab volumes
Slide 7: A new AST segment: Creating a new gold standard diagnostic segment
A new AST segment | Creating a new ”gold standard” diagnostic segment Informational Current Standard-of-Care Emerging Gold Standard Future potential technologies value Colony-based AST Positive Blood Culture AST Whole Blood AST • No technologies approved today • Current ’standard-of-care’ • Needed f
Slide 8: Customer landscape: ASTar aimed at largest labs representing majority of market
Customer landscape | ASTar aimed at largest labs representing majority of market US blood culture (BC) sets taken annually1 25,0 ~24m 3,7 5 – 10k BC sets / yr | >4,000 labs Small & 20,0 very small 4,2 5 – 10k BC sets / yr | 818 labs • ASTar optimised for labs with >1,000 positive blood 15,0 cultures
Slide 9: US commercial targeting: Emphasis on top tier hospitals and reference labs
US commercial targeting | Emphasis on top tier hospitals and reference labs Locations of largest hospital labs, reference labs and IDNs across US ❖ US commercial team has already contacted roughly half of the top 250 labs in the country since FDA approval (in April) ❖ Of those contacted, close to ha
Slide 10: Funnel dynamics: Typical buying cycle for major diagnostic lab equipment
Funnel dynamics | Typical buying cycle for major diagnostic lab equipment 12 – 18 months is ‘normal’ timeframe for end-to-end engagement-to-install process 4 – 6 mths 3 – 6 mths 2 – 6 mths 1– 3 mths INITIAL CUSTOMER CUSTOMER DEMO PURCHASE PROCESS INSTALL & GO LIVE ENGAGEMENT & EVALUATION & NEGOTIATI
Slide 11: Clinical impact: Results emerging from US Early Access Program partnerships
Clinical impact | Results emerging from US Early Access Program partnerships Significant patient outcomes improvement anticipated from reduced time-to-result Highlights from US EAP presented by Dr. Yee of George Washington University • Three US EAP programs have completed, publications being drafted
Slide 12: Financial highlights: During (and after) third quarter
Financial highlights | During (and after) third quarter • Cost savings show (almost) full effect in Q3 2024 • Loan facilty from main owner Nexttobe (May 29) • Existing, unutlized facilty as of 30 September: SEK 23 million • Cash at bank as of 30 September: SEK 7.5 million → Total: SEK 30.5 million •
Slide 13: Financial highlights: Rights issue + Bridge loan
Financial highlights | Rights issue + Bridge loan • Capital raise of approx. SEK 225 million in a rights issue of units where one unit consists of 2 common shares and 1 warrant • Transaction secured up to approx. 80 percent • Subscription price to be set at 30 % discount to TERP to the volume weight
Slide 14: Consolidated statement of profit and loss: Third quarter
Consolidated statement of profit and loss | Third quarter • Instrument sales and other operating income recorded, SEK 0.6 million (3.0) • Top-line is affected negatively short term by the use of reagent rental model • In short the reagent rental model has no capital sale of the instrument up-front b
Slide 15: Consolidated statement of financial position: End of third quarter
Consolidated statement of financial position | End of third quarter • Cash and cash equivalents amounted to SEK 7.5 million (81.9) • SEK 37 million in new loan from main owner Nexttobe received in second quarter • SEK 16.8 million average monthy burn rate for the second quarter • SEK 17.0 million av
Slide 16: Future financing
Future financing • As of 30 of Sepember we have a total of SEK 30.5 million in available funds, whereof cash at bank 7.5M and 23M in an unutlized, remaining loan facility from main owner. • Total loan facility amounts to SEK 101.5 million is now approved at the AGM and will mature 30 June 2026 • Rig
Slide 17: Thank you!
Thank you! Q-linea aims to contribute to a healthier society by future- proofing a new generation of healthcare professionals, labs and hospitals 17